SCHEMBL1845867

SCHEMBL1845867

C=CCC([NH])c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HTR2A P28223 2/20 0.36
TAAR1 Q96RJ0 1/20 0.36
CYP3A4 P08684 1/20 0.35
TSHR P16473 2/20 0.34
HRH1 P35367 1/20 0.33
MTOR P42345 1/20 0.33
RAB9A P51151 1/20 0.33
GRM7 Q14831 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL691762 0.78 CYP2C19 (0.57) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL3996056 0.76 CYP2C19 (0.55) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL9003499 0.76 CYP2C19 (0.55) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
Ammonia Solution, Strong SCHEMBL11201030 0.76 CYP2C19 (0.55) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL7674344 0.76 CYP2C19 (0.55) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL5732595 0.73 CYP2C19 (0.57) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL19285046 0.73 TAAR1 (0.52) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL5733567 0.73 CYP2C19 (0.57) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL96509 0.73 CYP2C19 (0.57) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL1121969 0.73 CYP2C19 (0.52) CYP2C19SMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322222-A1 THERAPEUTIC AGENT FOR IRRITABLE BOWEL SYNDROME Takeda Pharmaceutical Company Limited (JP) 2011-05-18 EP disclosed
WO-2006058299-A2 MANUFACTURE OF LIMONOID COMPOUNDS THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2006-06-01 WO disclosed
US-20060116509-A1 Manufacture of limonoid compounds THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 2006-06-01 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed
EP-0415634-A2 Benzazabicyclic carbamates as cholinesterase inhibitors PFIZER INC. (US) 1991-03-06 EP disclosed
US-4082679-A LIGHT STABILIZED TEXTILE MINERAL OIL WITCO CHEMICAL CORPORATION (US) 1978-04-04 US disclosed